NICE has set out its plan using four key pillars designed to elicit incremental change within the UK...
Read moreThe highly specialised technologies (HST) process was introduced in 2013 for the purpose of evaluati...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreFollowing Brexit, the Medicines and Healthcare Regularoty Agency (MHRA) has become the UK's sole bod...
Read moreThis study aimed to assess whether the new process has resulted in changes to outcomes of STAs.
Read moreThis study aimed to review timelines and use of financial agreements for products being appraised.
Read moreA recent study assessed whether this new process has resulted in faster patient access.
Read more... and the use of financial arrangements for new oncology and non-oncology drugs?
Read moreICER’s Health Technology Assessments review process is an assessment undertaken by one of three ap...
Read moreThis newsletter will discuss the early access processes operating within the UK and discuss the adva...
Read more